ARFONAD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARFONAD is a small-molecule injectable approved in 1954 by Roche for intravenous administration. The specific mechanism of action and therapeutic indication are not publicly detailed in available data, though its 70-year history suggests use in acute or perioperative settings. As a legacy product approaching loss of exclusivity, it represents a declining but established therapeutic agent.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), indicating a mature, low-growth brand with minimal headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARFONAD offers minimal career growth opportunities given zero linked job openings and approaching loss of exclusivity. Roles are likely focused on compliance, transition management, and cost control rather than market expansion or innovation.
Brand ManagerMedical Science Liaison
Worked on ARFONAD at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.